X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, GreenLight Biosciences and Epivax Therapeutics will design and develop new personalized mRNA-based cancer vaccine candidates using GreenLight and EpiVax Therapeutics technology platforms.
Lead Product(s): mRNA-based Vaccine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Recipient: GreenLight Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 09, 2023
Details:
Avacc 101 is Intravacc subunit betacoronavirus vaccine candidate. Avacc 101 vaccine candidate will be designed to provide broad protection against SARS-CoV-1, SAR-CoV-2, and MERS-CoV.
Lead Product(s): Avacc 101
Therapeutic Area: Infections and Infectious Diseases Product Name: Avacc 101
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Intravacc
Deal Size: $4.8 million Upfront Cash: Undisclosed
Deal Type: Collaboration November 01, 2022
Details:
EpiVax was tapped by Leidos to conduct in silico T cell epitope prediction, for both HLA Class I and Class II epitopes in malaria vaccine blood stage antigens. The in silico predictions were subsequently used to inform ex vivo assessment by University of Oxford scientists.
Lead Product(s): Malaria Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Partner/Sponsor/Collaborator: Leidos
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 17, 2021
Details:
In a preclinical immunization study in HLA- transgenic mice, EPV-CoV-19 stimulated a strong type 1-skewed T cell response, that is characteristic of safe COVID-19 vaccines.
Lead Product(s): EPV-CoV19
Therapeutic Area: Infections and Infectious Diseases Product Name: EPV-CoV19
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2021
Details:
EpiVax, Inc. has out-licensed its COVID-19 vaccine candidate, EPV-CoV-19, to EpiVax Therapeutics, a New York-based company previously named EpiVax Oncology.
Lead Product(s): EPV-CoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: EPV-CoV-19
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: EpiVax
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 24, 2020
Details:
Intravacc will combine its immunogenic OMV delivery platform with synthetically produced COVID-19 epitopes, designed and optimized by EpiVax using advanced immunoinformatics tools to generate safe & highly effective T-cell response against SARS-CoV-2 and related coronaviruses.
Lead Product(s): OMV-peptide vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Intravacc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 02, 2020
Details:
This partnership will combine the Entos Fusogenix DNA delivery technology with optimized COVID-19 epitopes from EpiVax to generate a highly effective immune response against the novel coronavirus.
Lead Product(s): Fusogenix
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Entos Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 28, 2020
Details:
This collaboration will combine Immunomic’s UNITE platform, EpiVax’s in silico T cell epitope prediction tool, and PharmaJet’s well established Tropis® Needle-free Injection System.
Lead Product(s): Nucleic acid vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Immunomic Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 09, 2020
Details:
This partnership aims at crowd-source funds for the development of EpiVax's COVID-19 vaccine candidate (EPV-CoV19) for healthcare workers.
Lead Product(s): EPV-CoV19
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: GAIA Vaccine Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 07, 2020
Details:
EpiVax to use Generex's computational tools to predict epitopes that can be used to generate peptide vaccines against the nCOV-2019 using the patented NuGenerex Immuno-Oncology .
Lead Product(s): Li-Key peptide vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Generex Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
